Replimune Group, Inc. (NASDAQ:REPL) Receives $19.14 Average Price Target from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $19.14.

Several analysts recently weighed in on REPL shares. BMO Capital Markets lifted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Jefferies Financial Group upped their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright upped their price target on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd.

Insider Buying and Selling

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

A number of hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP boosted its holdings in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Braidwell LP grew its holdings in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares during the period. State Street Corp raised its position in Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of Replimune Group stock opened at $14.02 on Friday. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The stock has a market capitalization of $959.25 million, a P/E ratio of -4.60 and a beta of 1.28. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The business has a 50 day simple moving average of $12.40 and a two-hundred day simple moving average of $11.42.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, analysts predict that Replimune Group will post -2.88 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.